Cyplasin-SC(TM) Enters Next Phase of Efficacy Animal Testing



    CYPL: OTCBB

    EDMONTON, Oct. 5 /CNW/ - In recent third party validated cell based
laboratory tests, Cyplasin-SC(TM) has shown a unique toxicity to many tumor
cells, including human melanoma cells. However normal human cells are not
affected by Cyplasin-SC(TM) at concentrations used to kill the tumor cells.
    These positive validated results allowed the Company to take
Cyplasin-SC(TM) into dosing experiments in animals. The first question that
was answered: what is the highest tolerated dosage and is it safe? A Contract
Research Organization, AURIGON Life Sciences, Tutzing, Germany, performed the
dose ranging studies.
    The experiments were devised such that other questions could also be
answered: What is the highest dose of Cyplasin-SC(TM) to be tolerated when
injected only once? What is the highest dose of Cyplasin-SC(TM) to be
tolerated when injected repeatedly and what is the best time interval for the
injections? What is the best mode of application either under the skin
(subcutaneously), or into a vein (intravenously), or into the body cavity
(intraperitoneally)?
    Positive results from these studies were obtained as all mice injected
with Cyplasin-SC(TM) at concentrations toxic for the human melanoma cells
survived and the results showed Cyplasin-SC(TM) was well tolerated by the
organism. The best application form appears to be a subcutaneous application
where Cyplasin-SC(TM) is injected under the skin.
    This will prove to be very advantageous for the next series of animal
efficacy experiments where the mice will bear a human melanoma tumor growing
on the surface of the animal and Cyplasin-SC(TM) will be injected in the
vicinity of the tumor so as to exert its toxic effect as close to the cancer
target as possible. Positive results from these experiments will then allow
Cyplasin-SC(TM) to move to next step toxicology studies.

    About Melanoma

    Market statistics for skin cancer and melanoma show that melanoma
currently affects more then 2.4 million people worldwide. In the US more than
62,000 new cases are reported every year, as fair-skinned and sunbelt
populations are at high risk for the disease. Australia has the highest rate
of melanoma in the world among males and has the second highest rate in the
world among females (Australia's Health 2004, AIHW). Overall the world wide
incidence has doubled over the past 20 years.

    About Cyplasin-SC(TM)

    Cyplasin-SC(TM) has demonstrated a selective ability to rapidly kill
melanoma cancer cells while leaving normal non-cancerous cells untouched.
Cyplasin is a protein originally discovered and isolated by Professor Petzelt
from a marine organism, the sea hare (Aplysia punctata). The protein can now
be manufactured as a recombinant protein which allows the company to develop
the protein as a potential anticancer therapeutic product. Patents have been
issued to the Company covering the Cyplasin protein.

    About Cyplasin Biomedical Ltd. (CBL)

    Founded in 2007 and headquartered in Edmonton, Alberta, Canada with a
research laboratory close to Berlin, Germany, CBL is dedicated to bringing new
anticancer therapeutics to the marketplace. The Company's current goal is to
develop and commercialize the anticancer properties of Cyplasin-SC(TM) for
skin cancers and melanomas. CBL is publicly traded (CYPL: OTCBB).

    Forward-Looking Statements

    This press release includes and is based, inter alia, on forward-looking
information and statements that are subject to risks and uncertainties that
could cause actual results to differ. Such forward-looking information and
statements are based without limitation, as statements regarding future drug
development activities, anticipated products, or anticipated future revenues,
benefits or advantages, and the future plans and objectives of the Company,
that involve inherent risks and uncertainties and are subject to factors, many
of which are beyond the Company's control, such as market acceptance of new
products and services, changes in governmental regulations, interest rates,
fluctuations in currency exchange rates and such other factors as may be
discussed from time to time that may cause actual results or performance to
differ materially from those currently anticipated in such statements. These
expectations, estimates and projections are generally identifiable by
statements containing words such as "expects", "believes", "estimates" or
similar expressions. Although Cyplasin Biomedical Ltd., believes that its
expectations and the information in this Press release were based upon
reasonable assumptions at the time when they were made, it can give no
assurance that those expectations will be achieved or that the actual results
will be as set out in this Press release. Cyplasin Biomedical Ltd., makes no
representation or warranty, expressed or implied, as to the accuracy,
reliability or completeness of the information in the Press release, and
neither Cyplasin Biomedical nor any of their directors, officers or employees
will have any liability to you or any other persons resulting from your use of
the information in the Press release. The OTCBB Exchange has not reviewed and
does not accept responsibility for the adequacy or accuracy of this news
release.





For further information:

For further information: Garth Likes, President & CEO, Cyplasin
Biomedical Ltd., Direct phone (780) 469-CYPL(2975), Email Address:
glikes@cyplasin.com, FAX Number (780) 699-7933, Website URL: www.cyplasin.com

Organization Profile

CYPLASIN BIOMEDICAL LTD.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890